Sully Drotar, DO
Obesity Medicine · Dallas, TXNPI 1861874703
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $176,218 of the $193,574 with a category attached, or 91.0%. Lilly USA, LLC accounts for 67.5% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $123,438, more than ten times the $1,127 reported in 2019.
Across 380 payments — averaging $509.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$131K
- Novo Nordisk$60K
- Abbott$861
- Corcept Therapeutics$377
- AstraZeneca$362
- Idorsia Pharmaceuticals US Inc$263
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$176,21891%
- Travel & lodging$8,0904%
- Food & beverage$9,1955%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 207 | $130,697 |
| Novo Nordisk | 97 | $59,641 |
| Abbott | 10 | $861 |
| Corcept Therapeutics | 13 | $377 |
| AstraZeneca | 4 | $362 |
| Idorsia Pharmaceuticals US Inc | 4 | $263 |
| GSK | 13 | $206 |
| Amarin Pharma, Inc. | 6 | $190 |
| Pfizer | 3 | $150 |
| AbbVie(2 entities) | 3 | $148 |
| Rhythm Pharmaceuticals, Inc. | 5 | $146 |
| Bayer | 2 | $136 |
| Gilead | 1 | $115 |
| Actelion Pharmaceuticals US, Inc. | 1 | $63 |
| Vivus LLC | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Soleno Therapeutics, Inc. | 1 | $30 |
| Aroa Biosurgery Incorporated | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $12 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few obesity medicine providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 134 | $147,325 |
| OzempicSemaglutide | 82 | $91,395 |
| JardianceEmpagliflozin | 25 | $26,578 |
| WegovySemaglutide | 18 | $23,163 |
| FarxigaDapagliflozin Propanediol | 18 | $19,402 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $5,415 |
| Lisdexamfetamine Dimesylate | 16 | $5,166 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $1,776 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $1,004 |
| Bupropion XlBupropion Hcl | 46 | $974 |
| Topiramate | 88 | $512 |
| Ondansetron OdtOndansetron | 33 | $413 |
| Duloxetine Hcl | 16 | $351 |
| Rosuvastatin Calcium | 20 | $342 |
| Metformin Hcl ErMetformin Hcl | 58 | $293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $130,697 | $147,325134 claims |
| Novo NordiskOzempic, Wegovy | $59,641 | $114,557100 claims |
| AstraZenecaFarxiga | $362 | $19,40218 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $34 | $5,41512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Texason file to place this against a meaningful peer group, so we don't.
Other obesity medicine in Dallas
- Christina UlbrichDallas$793
- Sameer MuraliHouston$93K
- Alan GlombickiHouston$93K
- Suzanne CudaSan Antonio$40K
- Michael SegerSan Antonio$16K
- Richa MittalFrisco$8K
- Kurt ReyesMcKinney$4K
- Laura MontesMcAllen$1K
- Michele CaveneePlano$363
- Ryan RatliffTyler$332
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.